Recent IPO activity shows renewed breadth across U.S. and European markets, with large listings and filings spanning restaurants, consumer retail, fintech, digital infrastructure, defence, telecom and healthcare real estate. In the U.S., Jersey Mike’s, Nutrabolt, iHerb and several Nasdaq debutants highlight stronger investor appetite, while Europe’s pipeline includes KNDS, Dusk, Infracore, Digi Spain and Smag. Although market volatility remains a constraint, IPO momentum appears to be broadening beyond AI-led growth stories and defensive consumer names across public equity markets today.

IPOX® CEO Josef Schuster told Reuters that Londian Wason New Energy Tech’s U.S. IPO filing could mark an important step for larger Chinese issuers seeking access to U.S. equity markets. Schuster noted that, if successful, the offering may help reopen the U.S. IPO market for bigger China-based deals. He also highlighted Londian’s position as a leading manufacturer of a key battery component, suggesting the company could attract investor interest despite pending pricing details.

IPOX® Associate Muehlbauer commented on Jersey Mike’s U.S. IPO filing in Reuters, noting the sandwich chain’s clear franchise-driven investment story, reported revenue growth, expansion plans and Blackstone backing. He also said the proposed listing could test investor appetite for restaurant IPOs, a category with mixed aftermarket performance. Reuters reported that Jersey Mike’s operates more than 3,300 locations across the U.S. and Canada and plans to list on the New York Stock Exchange under ticker JMKE as public markets reopen broadly.

IPOX® VP Kat Liu commented on Cumberland Farms’ IPO filing in Reuters coverage of the convenience store retailer’s move toward a Nasdaq listing. Liu noted that the IPO market’s reopening has broadened beyond AI and other high-growth sectors, with companies from a wider range of industries coming to market. She also said investors may view Cumberland Farms as a defensive retail business with stable cash flows rather than a traditional consumer discretionary company amid the renewed IPO momentum in 2026.

IPOX® Research Associate Lukas Muehlbauer was quoted in Reuters on ITG’s Nasdaq debut, saying: “The current buzz around the AI and data center theme helped ITG to go public, with investors still looking for companies that can benefit from the rising demand around digital infrastructure.” Reuters reported that ITG shares rose 12.5%, valuing the Oaktree-backed digital infrastructure company at $2.18 billion and highlighting investor demand for companies tied to AI infrastructure.

IPOX® Associate Muehlbauer commented on the debut of mobility firm Lime in Reuters. The Uber-backed e-scooter and bike operator opened above its $25 IPO price, valuing the company at about $1.73 billion. Muehlbauer said the pricing and first-day trading indicated sufficient investor demand, though the reception appeared measured. He added that Lime must prove it can sustain growth through seasonal and market cycles without relying mainly on adding vehicles and capex in a competitive sector.

Global IPO activity remained robust, led by U.S. technology, industrial, mining, insurance, and mobility listings, including OpenAI’s delayed IPO plans, Bending Spoons’ US$1.62bn Nasdaq deal, and Doncasters’ strong debut. Europe saw defense, real estate, retail, and IPO research updates, while Asia-Pacific featured Shenzhen’s record China Resources New Energy IPO, plus Hong Kong and ASX candidates, underscoring broad investor appetite across regions, despite some postponements and withdrawals.

Reuters reported that Mexican silver miner Sinda fell 10% in its NYSE debut after raising $213 million in its U.S. IPO. IPOX® Research Associate Lukas Muehlbauer was quoted on the selective IPO window for mining firms, noting that pre-production miners face investor scrutiny because their value depends on long-term execution. He also highlighted Sinda’s “high-risk, high-reward profile,” citing its appealing location and experienced backing alongside the uncertainty of exploration-stage mining companies in the current market for metals producers and explorers.

Reuters featured IPOX® Associate Lukas Muehlbauer in two articles covering Doncasters’ U.S. IPO and NYSE debut. The aerospace parts maker raised $919.3 million after pricing above its marketed range, then opened 33.3% higher in its first trading session. Muehlbauer discussed Doncasters’ nearly 250-year heritage, post-2020 turnaround, revenue growth, and broader positioning across aerospace, defense, industrial gas turbines, and AI-linked power demand, noting that its investment story extends beyond a pure-play defense theme for Reuters readers following IPO markets closely.

IPOX CEO Josef Schuster commented on Safepoint’s decision to withdraw its planned U.S. listing, telling Reuters that the move appeared to reflect company-specific factors rather than weakness in the broader IPO market. The Florida insurer had sought to raise up to $283.3 million after launching its IPO in May. Reuters noted that the withdrawal came as the IPO market continued to regain momentum, with several Florida-based insurers already completing New York listings in 2025, following recent reforms in Florida’s market.

IPOX® CEO Josef Schuster featured on the First Trust ROI Podcast to discuss post-IPO performance trends, renewed activity in the IPO market, and key dynamics shaping new listings. Schuster highlighted IPOX® research on the long-term divergence between IPO winners and underperformers, the role of diversification in post-IPO investing, and opportunities across IPOs, spin-offs, SPACs, and international markets as investor interest in newly public companies continues to strengthen.

IPOX® Associate Muehlbauer commented on Lime’s planned U.S. IPO in Reuters, highlighting the Uber-backed electric bike and scooter operator’s global scale, cash generation, and strong revenue growth as supportive factors for its proposed valuation of up to $1.66 billion. His analysis also noted key market considerations, including seasonality, regulation, asset intensity, and city-level permit exposure, as Lime prepares to list on Nasdaq under the ticker LIME.

IPOX® Associate Muehlbauer was quoted by Reuters on Kardigan’s Nasdaq debut, after the heart drug developer raised $400 million in an upsized IPO. He noted that biotech IPO activity has improved but remains selective, favoring companies with late-stage assets, clear commercialization paths, visible catalysts, or strong backers. In broader commentary shared with Reuters, Muehlbauer said Kardigan’s going-concern warning was not a deal breaker and reflected why the company raised capital, while follow-on offerings remain a possible overhang for investors.

U.S. IPO news included SpaceX’s post-debut pullback, Doncasters’ planned listing at up to a $4.43 billion valuation, Brookfield-backed Csquare’s NYSE filing amid AI infrastructure demand, and renewed SPAC interest. Asia-Pacific activity featured Mynt’s Philippine IPO targeting $1 billion and an $8 billion valuation, MetaX’s planned Hong Kong listing of at least $1 billion, Xiaohongshu’s Hong Kong IPO ambitions, Alebund’s $200 million–$300 million Hong Kong IPO, and Qiandaohu’s $150 million–$200 million caviar IPO pipeline across U.S. and Asia-Pacific markets this week.

IPOX® VP Kat Liu was quoted by Reuters on SpaceX’s post-IPO share decline, as the stock fell more than 6% after a sharp debut rally. Reuters reported that shares remained over 30% above the $135 offering price, while investors weighed valuation, limited float, retail activity and AI expansion plans. Liu noted that profit-taking was not surprising given the IPO’s scale and strong initial performance, calling it an eventful, shortened trading week for the largest IPO in history.

IPOX® Associate Muehlbauer noted in Reuters coverage that some companies previously considering a traditional IPO may now look to SPAC mergers as mega-IPOs compete for investor attention. He said existing SPAC vehicles still need to complete transactions before liquidation, leaving capital actively seeking deals. Reuters highlighted renewed SPAC activity and rising issuance, while IPOX® data show the IPOX® SPAC Index outperforming the S&P 500 year to date, up 16.43% versus 9.73% amid a more favorable public-market backdrop for new listings.